Personalized cancer chemotherapy : an effective way of enhancing outcomes in clinics / / Da-Yong Lu

• Record Nr.: UNINA9910822907703321
• Autore: Lu Da-Yong
• Pubbl/distr/stampa: Cambridge, England : , : Woodhead Publishing, , 2015; ©2015
• ISBN: 0-08-101622-0; 0-08-100347-1
• Descrizione fisica: 1 online resource (85 p.)
• Collana: Woodhead Publishing Series in Biomedicine
• Disciplina: 615.58
• Soggetti: Chemotherapy; Cancer - Treatment
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references at the end of each chapters.
• Nota di contenuto: Front Cover; Personalized Cancer Chemotherapy: An Effective Way of Enhancing Outcomes in Clinics; Copyright; Contents; List of figures and tables; Figures; Tables; About the author; Preface; References; List of abbreviations; 1 - Introduction; References; 2 - Drug sensitivity testing; 2.1 History of drug sensitivity testing; 2.2 Methodology of drug sensitivity testing [6-7]; 2.3 Comparison between in vivo and in vitro drug sensitivity testing methodologies [6-7]; 2.4 Relationship of drug responses in drug chemosensitivity testing and clinical tumor treatment; 2.5 Possible reasons for unsatisfactory survival rates in spite of using drug sensitivity testing2.6 Cytotoxic and cytostatic anti-cancer drugs?; 2.7 Conclusion; References; 3 - Individualized cancer chemotherapy via cancer biomarkers or bioinformatics detection; 3.1 Cancer biomarkers and cancer bioinformatics for ICC [1-3]; 3.2 Seeing is predicting; 3.3 New challenges; 3.4 Discussion; 3.5 Other considerations; 3.6 Mathematical modeling and computational networks as assistant systems; 3.7 Finding tumorigenic markers from the genome to predict anticancer drug responses; 3.8 Future directions; References4 - Pharmacogenetics; 4.1 Background; 4.2 Introduction; 4.3 Architectural framework of an anticancer drug pharmacogenetics or pharmacogenomics study; 4.4 Examples; 4.5 Discussion; References; 5 - Individualized antimetastatic therapy [1-2]; 5.1 Background; 5.2 Will ; antimetastatic therapy differ from antiproliferative therapy?; 5.3 Therapeutic mechanisms of the current antimetastatic drugs; 5.4 Drawbacks of current clinical antimetastatic therapy; 5.5 Should human tumor metastasis be treated according to clinical situations -individualized antimetastatic therapy? [19,21-22]...; 5.6 Find more metastatis-related molecules and develop novel types of antimetastatic drugs5.7 Targeting formed metastatic foci in clinics; 5.8 Discussion; 5.9 Conclusion; References; 6 - Drug combinations; 6.1 Introduction; 6.2 Cytotoxic drugs and biotherapy; 6.3 The advantages of a strategy of combining cytotoxic anticancer drugs and biotherapy; 6.4 Combined use of both antiproliferative drugs (primary tumor) and antimetastatic drugs; 6.5 Combined cytotoxic drugs and cytostatic drugs; 6.6 Rules of drug combination; 6.7 Conclusion; References; 7 - Assistant chemotherapy; 7.1 Anti-thrombosis therapy7.2 Antidepressant therapy; 7.3 Improving patients' physiological conditions; 7.4 Conclusion; References; 8 - Cost-effectiveness considerations; 8.1 Background; 8.2 Routine cost of cancer chemotherapy; 8.3 Calculation of cost-effectiveness; 8.4 The keys to the study of cost-effectiveness in individualized cancer chemotherapy; 8.5 Future trends; 8.6 Conclusion; References; 9 - Discussion; 9.1 Drug sensitivity testing; 9.2 The development of cancer biomarker detection; 9.3 Pharmacogenetics or pharmacogenomics; 9.4 Antimetastatic therapy; 9.5 Should antimetastatic drugs be offered to all cancer patients?
• Sommario/riassunto: Individualized cancer chemotherapy (ICC) has been designed to meet the requirement of selecting anticancer drugs in clinics and attracting increasing attentions in medical circle and will show more beneficial outcome in the future if we stick on these researches. Personalized Cancer Chemotherapy addresses and reviews this issue by discussing many existing specific strategies of ICC, including drug sensitivity testing, cancer biomarker detections, cancer biomarker-oriented therapy, anticancer drug pharmacogenetics, cancer metastasis therapy, anticancer drug combinations, assistant therapy, mat